Navigation Links
Convergence Pharmaceuticals Announces Successful Completion of Phase I for CNV2197944 and Plans Phase II Studies in Neuropathic Pain
Date:7/18/2012

CAMBRIDGE, England, July 18, 2012 /PRNewswire/ --

Phase I study data indicates CNV2197944's optimal profile for a chronic pain medication

Convergence Pharmaceuticals Limited ("Convergence"), the company focused on the development of novel and high value analgesic medicines for the treatment of chronic pain, today announces that it is designing Phase II proof of concept studies with CNV2197944 in neuropathic pain, following successful completion of Phase I. This novel, small molecule, state-dependent calcium channel blocker, is designed to selectively inhibit highly active Cav2.2 channels. It is the only truly selective Cav2.2 blocker in clinical development and has the potential to be a first in class treatment for chronic pain. Convergence is conducting the development of CNV2197944 on behalf of Calchan Ltd.

Results of the Phase I, placebo-controlled, multiple ascending dose clinical study with orally administered CNV2197944, demonstrated that the drug was well tolerated in all subjects, with few adverse events reported at doses that are expected to fall within the predicted therapeutic range. The compound was also well absorbed following oral administration, with a pharmacokinetic profile that is predictable and consistent in both young and elderly subjects.  These characteristics indicate CNV2197944's optimal profile for a chronic pain medication.

In view of these favourable data, well powered Phase II proof of concept trials for CNV2197944 in neuropathic pain are now being planned.

CNV2197944 - a first in class molecule with potential to be a first in class treatment

CNV2197944 is a novel, small molecule, state-dependent calcium channel blocker, designed to selectively inhibit highly active Cav2.2 channels. Preclinical studies demonstrated that CNV2197944 could have analgesic potential for a broad range of chronic pain conditions. Extensive safety and toxicology studies to support the clinical development of CNV2
'/>"/>

SOURCE Convergence Pharmaceuticals Ltd
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. The Convergence of Art, Science and Beer
2. Convergence Pharmaceuticals Initiates Phase I Multiple Ascending Dose Study for CNV2197944
3. Oramed Pharmaceuticals Granted 2nd Patent in New Zealand; 3rd Patent for Core Technology on Oral Delivery of Proteins
4. Keryx Biopharmaceuticals to Present at The 7th Annual JMP Securities Healthcare Conference
5. Auxilium Pharmaceuticals, Inc. to Present At The JMP Securities 2012 Healthcare Conference
6. Access Pharmaceuticals to Report New MuGard Clinical Trial Data This Week at the MASCC/ISOO Symposium in New York City
7. Keryx Biopharmaceuticals Announces Live Webcast of Upcoming Analyst Day
8. Auxilium Pharmaceuticals, Inc. to Present at the Jefferies 2012 Global Healthcare Conference
9. Questcor Pharmaceuticals to Present at Jefferies 2012 Global Healthcare Conference
10. Questcor Pharmaceuticals Expands Repurchase Program
11. Eutropics Pharmaceuticals Receives U.S. Patent for Novel Diagnostic Method
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/21/2014)... Calif. (PRWEB) November 20, 2014 ... nonprofit, public policy research organization representing leading California ... firms, and PwC US today released ... in life sciences industry growth. The trend shows ... The 2015 California Biomedical Industry Report ...
(Date:11/21/2014)... (PRWEB) November 20, 2014 BlueInGreen, ... Ozone Solutions, LLC (Pinnacle), and PCI, Inc., leading ... that they have been selected to provide a ... Fayetteville, Arkansas Paul R. Noland Wastewater Treatment. ... patented HyDOZ® gas dissolution technology, Pinnacle ...
(Date:11/21/2014)... Dallas, Texas (PRWEB) November 21, 2014 ... Industry” is a professional and in-depth research report ... information, including its definition, classification, application, and industry ... research covers the international market analysis, including China’s ... covering macroeconomic environment & economic situation analysis. The ...
(Date:11/21/2014)... SAN DIEGO , Nov. 20, 2014  Cytori Therapeutics ... Marc Hedrick , M.D. will present live at VirtualInvestorConferences.com ... 4, 2014 TIME:    11:15 am PT / 2:15 ... this URL into your browser,s address bar: http://bit.ly/1B2KGaL ... time and receive event updates. This will ...
Breaking Biology Technology:California Healthcare Institute and PwC Report Boom in California’s Biomedical Industry 2California Healthcare Institute and PwC Report Boom in California’s Biomedical Industry 3California Healthcare Institute and PwC Report Boom in California’s Biomedical Industry 4City of Fayetteville Leads Nation with Innovative Ozone Technology 2City of Fayetteville Leads Nation with Innovative Ozone Technology 3City of Fayetteville Leads Nation with Innovative Ozone Technology 4International Transformer Industry - Analysis on Applications, Development & Forecasts Now Available at ReportsnReports.com 2International Transformer Industry - Analysis on Applications, Development & Forecasts Now Available at ReportsnReports.com 3Cytori Therapeutics to Provide Corporate Update and Investor Presentation on December 4 through a Live, Interactive Webcast 2Cytori Therapeutics to Provide Corporate Update and Investor Presentation on December 4 through a Live, Interactive Webcast 3Cytori Therapeutics to Provide Corporate Update and Investor Presentation on December 4 through a Live, Interactive Webcast 4
... Wis. - The life sciences provider Promega broke ground ... in the Fitchburg Center, located next to the existing Promega ... square feet located near Cheryl Parkway and Fish Hatchery Road, ... of which will be retail space. The expansion will provide ...
... Oshkosh, Wis. - Representatives from universities in Germany ... an agreement on Monday to begin a global master ... the Internet. , ,The program further expands upon the ... of the state are the borders of the university. ...
... . - An immunologist at the University of Wisconsin-Madison ... be named 2005 Pew Scholars in the Biomedical Sciences. ... and immunology, will receive $60,000 per year for the ... independent nonprofit organization that annually funds innovative research projects ...
Cached Biology Technology:UW-Oshkosh launching Global MBA with schools in Germany, India 2
(Date:11/21/2014)... -- C-Labs LLC, a leading provider of remote and ... announced the appointment of John Traynor to ... advisor to the firm, Mr. Traynor will now oversee ... out of the C-Labs office in Redmond, ... , Chief Executive Officer. Photo - ...
(Date:11/18/2014)... 17, 2014 The Parenteral Drug Association (PDA) today ... will speak and at least seven more will participate in ... Omni Shoreham Hotel in Washington D.C. , ... have significant support from the regulatory agencies in ... in our effort to help advance the use of ...
(Date:11/11/2014)... 2014  Forensicon, Inc., a Chicago ... announce the promotion of Yaniv Schiff from ... In Schiff,s new role as Director, he will lead ... forensics examiners and provide leadership within the company,s digital ... http://photos.prnewswire.com/prnh/20141110/157719 Schiff joined Forensicon in ...
Breaking Biology News(10 mins):C-Labs Names Former Microsoft and Bsquare Executive as Chief Operating Officer 2FDA's Janet Woodcock, EMA's Emer Cooke Headline PDA Quality Metrics Conference 2Yaniv Schiff Promoted to Director of Digital Forensics at Forensicon, Inc. 2
... target to treat depression and other mood disorders may ... the neurotransmitters which inhibit other cells) shown to contribute ... Medicine researchers report in a new study in the ... that people suffering from depression and other mood disorders ...
... the September issue of The FASEB Journal ... unavoidable when losing weight through exercise and diet. In the ... (RDA) of protein while adhering to a diet and exercise ... loss. Tripling the RDA of protein, however, failed to provide ...
... statins extend lives by lowering cholesterol levels and reducing the ... 2013 issue of The FASEB Journal ... may reduce the rate at which telomeres shorten, a key ... for using statins, or derivatives of statins, as an anti-aging ...
Cached Biology News:Penn study: Shutting off neurons helps bullied mice overcome symptoms of depression 2Doubling the daily allowance of protein intake with diet and exercise protects muscle loss 2
... N. Fernandez and G. Butcher (1998). • ... of much research in the immunology area. ... of MHC proteins and in their function ... now faced with the prospect of tackling ...
delta-like 1 homolog (Drosophila)...
ELISpot kit for human Granzyme B. Kits contain PVDF plates, capture & detection antibodies, streptavidin-ALP, BSA, Skimmed dry milk, BCIP/NTB substrate, and wash buffer...
SHEEP ANTI ECHIS OCCELATUS (VENOM)...
Biology Products: